Deborah Dunsire, Lundbeck CEO
Lundbeck tries to rush its FDA-approved migraine drug to China but fails PhIII trial
Sales of Lundbeck’s CGRP inhibitor Vyepti, first approved in the US in 2020 and earlier this year in Europe, doubled to more than $50 million …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
